Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database
Expert Opinion on Drug Safety · 2025
DOI: 10.1080/14740338.2024.2392003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Opinion on Drug Safety, 2025. Verfasst von Yinjing Hou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the program of Beijing Hope Run Special Fund of Cancer Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Selective RET-specific tyrosine kinase inhibitors (RET-TKIs) treat RET fusion-positive non-small cell lung cancer (NSCLC), but studies on their cardiovascular toxicities are limited. This study aimed to characterize the cardiovascular toxicities associated with selective RET-TKI in real-world settings. RESEARCH DESIGN AND METHODS: Data from the United States Food and Drug Administration Adverse Event Reporting System database from 1 January 2020 to 30 June 2023, were analyzed. Two disproportionality methods, information component and reporting odds ratio (ROR) were used. RESULTS: Both pralsetinib and selpercatinib showed positive signals for hypertension (pralsetinib: ROR: 5.25, 95% CI: 4.40-6.26; selpercatinib: ROR: 2.68, 95% CI: 1.87-3.82). Additionally, pralsetinib showed a positive signal for ischemic heart disease (ROR: 3.92, 95% CI: 2.94-5.23), and selpercatinib for torsade de pointes/QT prolongation (ROR: 2.65, 95% CI: 1.74-4.04). The median time to onset(TTO) of cardiovascular toxicities was 33 days (IQR: 9-73 days) for pralsetinib and 15 days (IQR: 10-50 days) for selpercatinib. The proportion of deaths, life-threatening events, and hospitalizations due to cardiovascular toxicities were 8.57%, 1.19%, and 31.43%, respectively, for total selective RET-TKI. CONCLUSIONS: Selective RET-TKIs are related to multiple cardiovascular toxicities. Pralsetinib was linked to ischemic heart disease, and selpercatinib to torsade de pointes/QT prolongation and thrombotic events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Xiayang Ren
Förderung
- the program of Beijing Hope Run Special Fund of Cancer Foundation of China
Zitieren
APA
Hou, Y., Ren, X., Chen, Y., & Wang, Y. (2025). Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2024.2392003
Vancouver
Hou Y, Ren X, Chen Y, Wang Y. Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database. Expert Opinion on Drug Safety. 2025. doi:10.1080/14740338.2024.2392003
BibTeX
@article{Hou2025,
author = {Hou, Yinjing and Ren, Xiayang and Chen, Ying and Wang, Yanfeng},
title = {Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database},
journal = {Expert Opinion on Drug Safety},
year = {2025},
doi = {10.1080/14740338.2024.2392003}
}
EUVIMED